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LETTER TO THE EDITOR
Erlotinib Effective
against Refractory
Bronchorrhea from
Advanced Non-small
Cell Lung Cancer
To the Editor:
Bronchorrhea is described as a
rare complication of bronchoalveolar
carcinoma.1 Here, we describe the treat-
ment of this condition with erlotinib, an
EGFR tyrosine kinase inhibitor. Our pa-
tient was a 59-year-old man with a 40-
pack-year history, who presented with a
relatively short, 2-week history of cough
with expectoration and shortness of
breath. A computed tomography scan
showed diffuse infiltrative changes in-
volving the right lung but also a right
hilar mass, mediastinal lymphadenopa-
thy, and a mass in the adrenal suggestive
of metastases. There was no intrabron-
chial tumor on bronchoscopy, and bi-
opsy only revealed areas of dysplasia
without invasion. The cytology report
indicated a non-small cell carcinoma.
The clinical and radiological features
were consistent with bronchoalveolar
carcinoma.2 He received a cycle of cis-
platinum and gemcitabine chemother-
apy, but he presented a week later, se-
verely short of breath and complaining
of a copious expectorate amounting to
more than 2 liters/day of mucoid spu-
tum. We tried antibiotics, amitryptiline
and hyoscine hydrobromide cutaneous
patch, octreotide and hyoscine butylbro-
mide subcutaneous infusions, and steroid
both locally (beclomethasone inhaler) and
systemically (dexamethasone), without
any significant benefit. Noting case re-
ports describing response of bronchor-
rhea to gefitinib,3 we offered him erlo-
tinib because we had access to the drug
on an expanded access program. There
was a remarkable turnaround, and spu-
tum production declined within just few
days of starting erlotinib (Tarceva, F.
Hoffmann-La Roche Ltd, Basel, Swit-
zerland). Serial chest x-rays showed
clearing of the patchy opacity involving
almost the entire right lobe within two
weeks, leaving only a residual abnor-
mality in the right upper lobe (see Fig-
ures 1 and 2). We tried a further two
cycles of chemotherapy with carboplatin
and paclitaxel, but they were tolerated
poorly and abandoned. Unfortunately,
he progressed 4 months after starting
erlotinib and died 2 months later. Erlo-
tinib was continued until a couple of
weeks of death, and he did not have a
recurrence of the distressing bronchorrhea.
Bronchorrhea is a rare complication
of bronchoalveolar carcinoma, and mucin
production has been linked to an EGFR-
related pathway. Takeyama et al.4 have
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FIGURE 1. Chest x-ray at presentation with bronchorrhea.
FIGURE 2. Chest x-ray 4 weeks after starting erlotinib.
Journal of Thoracic Oncology • Volume 2, Number 9, September 2007 881
shown that stimulation of EGFR by its
ligands, EGF and transforming growth
factor alpha, causes MUC5AC expression
in airway epithelial cells both in vitro and
in vivo. EGFR tyrosine kinase inhibitors
have been effective in the management of
advanced bronchoalveolar carcinoma.5
Experiments have also shown their effec-
tiveness in blocking mucin production in
cultured airway epithelial cells. Kitazaki et
al.6 suggest that gefitinib may inhibit
MUC5AC synthesis at least in part
through the MAPK and Akt signaling
pathways.
Our patient benefited significantly
from the use of erlotinib. Response was
seen within days of starting the drug. Nev-
ertheless, the cancer progressed after a few
months while the bronchorrhea remained
controlled, implying that the tumor was
somehow able to overcome its reliance on
the EGFR pathway for growth, whereas
the mucin production pathway remained
tied to EGFR stimulation and, therefore,
could be effectively blocked by EGFR
inhibitors.
Ziad Thotathil, MD, FRCR
Jeremy Long, FRACP
Department of Oncology Waikato Hospital
Hamilton, New Zealand
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